About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:3759844
Allelic
Composition
Il10tm1Cgn/Il10tm1Cgn
Genetic
Background
B6.129P2-Il10tm1Cgn/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Il10tm1Cgn mutation (14 available); any Il10 mutation (31 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Characterization of Il10tm1Cgn/Il10tm1Cgn mice

growth/size/body
• lower body weight gain between 5 and 10 weeks of age than for controls

immune system
• mutants develop severe inflammation in the colon leading to inflammatory bowel disease
• mice infected with T. muris exhibit increased worm burden and cecum score compared with similarly treated wild-type mice
• CD25-positive CD4 T cells from these mice fail to protect against the wasting disease induced by transferring nave CD4 T cells into immunodeficient hosts
• however, CD25-postive CD4 T cells inhibit the expansion of naive T cells in Rag2 deficient hosts as effectively as wild-type CD25-positive CD4 T cells
• levels of cytokines increase in the brain are greater than for controls after lipopolysaccharide treatment (J:139972)
• in LPS-injected mice (J:157787)
• plasma levels remain elevated for 24 hours after lipopolysaccharide treatment as opposed to 4 hours for controls (J:139972)
• in LPS-injected mice (J:157787)
• plasma levels remain elevated for 24 hours after lipopolysaccharide treatment as opposed to 4 hours for controls (J:139972)
• slightly in LPS-injected mice (J:157787)
• LPS-injected mice exhibit increased CXCL10 and CXCL1 levels compared with similarly treated wild-type mice
• mice infected with T. muris exhibit increased worm burden and cecum score compared with similarly treated wild-type mice

homeostasis/metabolism
• time to fatigue on a motorized treadmill is reduced 24% after lipopolysaccharide treatment
• increased toxicity of N-methyl-D-aspartate in primary neuron culture
• lipopolysaccharide causes a very significant drop in core body temperature
• levels of cytokines increase in the brain are greater than for controls after lipopolysaccharide treatment (J:139972)
• in LPS-injected mice (J:157787)
• plasma levels remain elevated for 24 hours after lipopolysaccharide treatment as opposed to 4 hours for controls (J:139972)
• in LPS-injected mice (J:157787)
• plasma levels remain elevated for 24 hours after lipopolysaccharide treatment as opposed to 4 hours for controls (J:139972)
• slightly in LPS-injected mice (J:157787)
• LPS-injected mice exhibit increased CXCL10 and CXCL1 levels compared with similarly treated wild-type mice
• lesion volume after middle cerebral artery occlusion increases 30%

digestive/alimentary system
• rectal prolapse is seen at a median time of 16 weeks of age
• 20% of mutants with colonic inflammation exhibit colon tumors; tumors are adenocarcinomas
• tumors develop between 25 and 35 weeks of age
• mutants develop severe inflammation in the colon leading to inflammatory bowel disease
• mice infected with T. muris exhibit increased worm burden and cecum score compared with similarly treated wild-type mice

cardiovascular system
• reduced choroidal neovascularization 7 days following krypton laser exposure of the eye
• LPS treatment markedly impairs contractions of the carotid artery induced by the thromboxane analogue U46619 and by phenylephrine
• endothelin 1 induced contraction of Aorta and first order mesenteric arteries is greater than controls when also treated with L-NAME and indomethecine and TNFalpha
• response to endothelin 1 is eliminated in the presence of PD-98059
• lower under basal conditions

muscle
• LPS treatment markedly impairs contractions of the carotid artery induced by the thromboxane analogue U46619 and by phenylephrine
• endothelin 1 induced contraction of Aorta and first order mesenteric arteries is greater than controls when also treated with L-NAME and indomethecine and TNFalpha
• response to endothelin 1 is eliminated in the presence of PD-98059

behavior/neurological
• rotarod performance worsens after IP lipopolysaccharide injection
• effect persists at least 24 hours
• performance fails to improve over consecutive trials but only after IP lipopolysaccharide injection
• more time in "slow-wave sleep" and less time awake during dark phase
• less effect of influenza virus infection on slow wave sleep during dark phase but a greater decrease in delta wave amplitude
• lipopolysaccharide causes an overall decrease in delta wave amplitude
• lipopolysaccharide causes decreased slow wave and REM sleep during light phase
• lipopolysaccharide results in increased time spent awake, particularly in light phase
• time to fatigue on a motorized treadmill is reduced 24% after lipopolysaccharide treatment

nervous system
• lesion volume after middle cerebral artery occlusion increases 30%
• increased sensitivity to oxygen or glucose deprivation
• increased toxicity of N-methyl-D-aspartate in primary neuron culture

vision/eye
• reduced choroidal neovascularization 7 days following krypton laser exposure of the eye

neoplasm
• 20% of mutants with colonic inflammation exhibit colon tumors; tumors are adenocarcinomas
• tumors develop between 25 and 35 weeks of age

cellular
• increased toxicity of N-methyl-D-aspartate in primary neuron culture

hematopoietic system
• CD25-positive CD4 T cells from these mice fail to protect against the wasting disease induced by transferring nave CD4 T cells into immunodeficient hosts
• however, CD25-postive CD4 T cells inhibit the expansion of naive T cells in Rag2 deficient hosts as effectively as wild-type CD25-positive CD4 T cells

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
inflammatory bowel disease DOID:0050589 OMIM:PS266600
J:124308 , J:149347


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
08/13/2019
MGI 6.14
The Jackson Laboratory